Register here

Date: November 23rd, 2017

Location: Hilton Congress Centre, Groenplaats, Antwerp, Belgium

Room: TBA

Program Chairs: Prof Dr Mervyn Singer, Prof Dr Luciano Gattinoni, Dr Paul Marik

Speakers:

Luciano Gattinoni, Milano, Italy
Paul Marik, Norfolk, USA
Mervyn Singer, London, UK
Sebastian Rehberg, Greifswald, Germany

Duration: 120 min

Pax: 40

Price: 125 EUR

Comment: This workshop can only be booked when attending the IFAD2017 meeting on Nov 24-25, 2017, at Hilton Congress Centre, Groenplaats, Antwerp, Belgium

Background: Definitions of sepsis and septic shock were last revised in 2001. Considerable advances have since been made into the pathobiology (changes in organ function, morphology, cell biology, biochemistry, immunology, and circulation), management, and epidemiology of sepsis, suggesting the need for reexamination. This formed the basis for the new Sepsis 3.0 definitions. Also recently the 4^th update of the surviving sepsis campaign guidelines was published. For the first time parameters assessing fluid responsiveness were included and the CVP criterion was abandoned. However when adhering to the SSCG, every patient with sepsis regardless of his/her comorbidities should receive 30 ml/kg in the first 3 hours according to the SEP-1 mandate.

Learning objective: This workshop will outline the basic principles in the treatment of sepsis and septic shock that underlie the need for individualized and personalized care. This workshop will help to understand the mechanisms of sepsis and how to implement the guidelines at the bedside. In analogy to antibiotic stewardship you will learn about sepsis stewardship. In this workshop different aspects will be discussed: the new sepsis 3.0 definitions, the updated surviving sepsis campaign guidelines, the risk of bundles of care, hot topic: decatecholaminisation in sepsis, and the future of sepsis care, given by top speakers, each experts in their field.

Draft scientific program (15min presentations with 10min for general discussion)

• 3:50 PM – 4:10 PM  
  Coffee Break
• 4:10 PM - 4:30 PM
  Introduction: Sepsis 3.0 how did we get there, a critical analysis? – Mervyn Singer
• 4:30 PM - 4:50 PM
  The new Surviving Sepsis Campaign Guidelines and the possible dangers of bundles – Paul Marik
• 4:50 PM - 5:26 PM
  Decatecholaminisation in sepsis: What, why, how and when? – Mervyn Singer; Paul Marik; Sebastian Rehberg; Luciano Gattinoni;
  • 4:50 PM - 5:02 PM
    The case of Vasopressin – Sebastian Rehberg
  • 5:02 PM - 5:14 PM
    the case of Levosimendan and the results of the LEOPARDS trial – Mervyn Singer
  • 5:14 PM - 5:26 PM
    the case for Betablockers – Sebastian Rehberg
• 5:26 PM - 5:50 PM
  The future of sepsis research and treatment and how common sense must prevail – Luciano Gattinoni
• 5:50 PM - 6:00 PM
  General Discussion – Mervyn Singer; Paul Marik; Sebastian Rehberg; Luciano Gattinoni;

Suggested reading:

1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. PMCID: PMC4968574 DOI: 10.1001/jama.2016.0287
2. Vandervelden S, Malbrain ML. Initial resuscitation from severe sepsis: one size does not fit all. Anaesthesiol Intensive Ther. 2015;47 Spec No:s44-55. DOI: 10.5603/AIT.a2015.0075
3. Angus DC, Barnato AE, Bell D, Bellomo R, Chong CR, Coats TJ, Davies A, Delaney A, Harrison DA, Holdgate A, Howe B, Huang DT, Iwashyna T, Kellum JA, Peake SL, Pike F, Reade MC, Rowan KM, Singer M, Webb SA, Weissfeld LA, Yealy DM, Young JD. A systematic review and meta-analysis of early goal-directed therapy for septic shock: the ARISE, ProCESS and ProMISe Investigators. Intensive Care Med. 2015 Sep;41(9):1549-60. DOI: 10.1007/s00134-015-3822-1
4. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017 Mar;43(3):304-377. DOI: 10.1007/s00134-017-4683-6
5. Malbrain ML, Marik PE, Witters I et al (2014) Fluid overload, de-resuscitation, and outcomes in critically ill or injured patients: a systematic review with suggestions for clinical practice. Anaesthesiol Intensive Ther. 46(5):361–380. DOI:10.5603/AIT.2014.0060
6. Gattinoni L, Ranieri VM, Pesenti A. Sepsis: needs for defining severity. Intensive Care Med. 2015 Mar;41(3):551-2. DOI: 10.1007/s00134-014-3598-8
7. Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study. Chest. 2017 Jun;151(6):1229-1238. DOI:10.1016/j.chest.2016.11.036